Does the media favor ACTU or SNOA?

In the previous week, Actuate Therapeutics had 12 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 15 mentions for Actuate Therapeutics and 3 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 1.45 beat Actuate Therapeutics' score of 0.79 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sonoma Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate AYTU or SNOA?

Aytu BioPharma currently has a consensus price target of $10.75, suggesting a potential upside of 357.45%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SNOA or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CLRB or SNOA?

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Sonoma Pharmaceuticals and 2 mentions for Cellectar Biosciences. Sonoma Pharmaceuticals' average media sentiment score of 1.45 beat Cellectar Biosciences' score of -0.87 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Sonoma Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ABVC or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Sonoma Pharmaceuticals (SNOA) Competitors

$1.35 +0.01 (+0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 +0.01 (+1.04%)

As of 04:51 PM Eastern

Compare

SNOA vs. ACTU, AYTU, TAOX, CLRB, and ABVC

Should you buy Sonoma Pharmaceuticals stock or one of its competitors? Sonoma Pharmaceuticals's main competitors and comparable companies include Actuate Therapeutics (ACTU), Aytu BioPharma (AYTU), Synaptogenix (TAOX), Cellectar Biosciences (CLRB), and ABVC BioPharma (ABVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sonoma Pharmaceuticals compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, Actuate Therapeutics had 12 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 15 mentions for Actuate Therapeutics and 3 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 1.45 beat Actuate Therapeutics' score of 0.79 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sonoma Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sonoma Pharmaceuticals has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
Sonoma Pharmaceuticals	$19.53M	0.33	-$3.17M	-$1.22	N/A

Actuate Therapeutics presently has a consensus target price of $13.67, suggesting a potential upside of 764.98%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Actuate Therapeutics is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Actuate Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Actuate Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Summary

Sonoma Pharmaceuticals beats Actuate Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sonoma Pharmaceuticals has a net margin of -10.33% compared to Aytu BioPharma's net margin of -60.17%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

Aytu BioPharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Aytu BioPharma currently has a consensus price target of $10.75, suggesting a potential upside of 357.45%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sonoma Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.38	-$13.56M	-$4.58	N/A
Sonoma Pharmaceuticals	$19.53M	0.33	-$3.17M	-$1.22	N/A

In the previous week, Sonoma Pharmaceuticals had 2 more articles in the media than Aytu BioPharma. MarketBeat recorded 3 mentions for Sonoma Pharmaceuticals and 1 mentions for Aytu BioPharma. Sonoma Pharmaceuticals' average media sentiment score of 1.45 beat Aytu BioPharma's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
Sonoma Pharmaceuticals	Positive

Summary

Aytu BioPharma and Sonoma Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Synaptogenix?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Sonoma Pharmaceuticals has higher revenue and earnings than Synaptogenix. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.33	-$3.17M	-$1.22	N/A
Synaptogenix	$300K	98.49	-$28.74M	-$3.85	N/A

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sonoma Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sonoma Pharmaceuticals has a net margin of -10.33% compared to Synaptogenix's net margin of -2,153.97%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

In the previous week, Sonoma Pharmaceuticals had 2 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for Sonoma Pharmaceuticals and 1 mentions for Synaptogenix. Sonoma Pharmaceuticals' average media sentiment score of 1.45 beat Synaptogenix's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Positive
Synaptogenix	Neutral

Summary

Sonoma Pharmaceuticals beats Synaptogenix on 8 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Cellectar Biosciences has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-185.35%	-115.42%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 333.07%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cellectar Biosciences is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cellectar Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Sonoma Pharmaceuticals and 2 mentions for Cellectar Biosciences. Sonoma Pharmaceuticals' average media sentiment score of 1.45 beat Cellectar Biosciences' score of -0.87 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Sonoma Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sonoma Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A
Sonoma Pharmaceuticals	$19.53M	0.33	-$3.17M	-$1.22	N/A

Summary

Cellectar Biosciences and Sonoma Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Sonoma Pharmaceuticals had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Sonoma Pharmaceuticals and 1 mentions for ABVC BioPharma. Sonoma Pharmaceuticals' average media sentiment score of 1.45 beat ABVC BioPharma's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ABVC BioPharma	Neutral
Sonoma Pharmaceuticals	Positive

ABVC BioPharma has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sonoma Pharmaceuticals has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	41.80	-$7.91M	-$0.30	N/A
Sonoma Pharmaceuticals	$19.53M	0.33	-$3.17M	-$1.22	N/A

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ABVC BioPharma has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

Summary

Sonoma Pharmaceuticals beats ABVC BioPharma on 8 of the 13 factors compared between the two stocks.

Get Sonoma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNOA vs. The Competition

Export

Metric	Sonoma Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.42M	$12.54B	$7.34B	$12.72B
Dividend Yield	N/A	2.61%	2.53%	11.02%
P/E Ratio	-1.11	778.14	270.94	24.14
Price / Sales	0.33	754.40	634.79	96.73
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	0.98	12.02	13.14	6.25
Net Income	-$3.17M	$2.80B	$3.46B	$347.86M
7 Day Performance	3.85%	3.95%	3.23%	1.57%
1 Month Performance	18.42%	6.54%	8.82%	5.24%
1 Year Performance	-72.05%	8.76%	27.70%	17.87%

Sonoma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNOA Sonoma Pharmaceuticals	1.1336 of 5 stars	$1.35 +0.7%	N/A	-73.7%	$6.42M	$19.53M	N/A	180	Positive News Short Interest Increase
ACTU Actuate Therapeutics	2.7099 of 5 stars	$1.06 +1.0%	$13.67 +1,189.3%	-85.3%	$25.37M	N/A	N/A	10	Short Interest Increase
AYTU Aytu BioPharma	2.2008 of 5 stars	$2.36 flat	$10.75 +355.5%	+5.0%	$25.32M	$66.38M	N/A	160	Positive News
TAOX Synaptogenix	0.1121 of 5 stars	$3.38 +5.0%	N/A	-48.9%	$25.26M	$772.50K	N/A	4	Positive News
CLRB Cellectar Biosciences	2.8831 of 5 stars	$2.66 +2.7%	$11.00 +313.7%	-48.4%	$25.13M	N/A	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNOA) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. ACTU, AYTU, TAOX, CLRB, and ABVC

How does Sonoma Pharmaceuticals compare to Actuate Therapeutics?

Summary

How does Sonoma Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Sonoma Pharmaceuticals compare to Synaptogenix?

Summary

How does Sonoma Pharmaceuticals compare to Cellectar Biosciences?

Summary

How does Sonoma Pharmaceuticals compare to ABVC BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. ACTU, AYTU, TAOX, CLRB, and ABVC

How does Sonoma Pharmaceuticals compare to Actuate Therapeutics?

Does the media favor ACTU or SNOA?

Which has better earnings and valuation, ACTU or SNOA?

Do analysts prefer ACTU or SNOA?

Is ACTU or SNOA more profitable?

Do insiders and institutionals hold more shares of ACTU or SNOA?

Which has more risk & volatility, ACTU or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to Aytu BioPharma?

Do insiders and institutionals hold more shares of AYTU or SNOA?

Is AYTU or SNOA more profitable?

Which has more volatility and risk, AYTU or SNOA?

Do analysts rate AYTU or SNOA?

Which has better valuation and earnings, AYTU or SNOA?

Does the media favor AYTU or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to Synaptogenix?

Which has better valuation & earnings, SNOA or TAOX?

Do insiders & institutionals have more ownership in SNOA or TAOX?

Which has more risk and volatility, SNOA or TAOX?

Do analysts prefer SNOA or TAOX?

Is SNOA or TAOX more profitable?

Does the media prefer SNOA or TAOX?

Summary

How does Sonoma Pharmaceuticals compare to Cellectar Biosciences?

Is CLRB or SNOA more profitable?

Do analysts rate CLRB or SNOA?

Which has more volatility & risk, CLRB or SNOA?

Do institutionals and insiders hold more shares of CLRB or SNOA?

Does the media favor CLRB or SNOA?

Which has preferable valuation & earnings, CLRB or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to ABVC BioPharma?

Does the media favor ABVC or SNOA?

Which has more risk and volatility, ABVC or SNOA?

Do analysts prefer ABVC or SNOA?

Which has stronger valuation & earnings, ABVC or SNOA?

Do insiders & institutionals have more ownership in ABVC or SNOA?

Is ABVC or SNOA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools